Tarsus Pharmaceuticals (TARS) Accumulated Expenses (2019 - 2026)

Tarsus Pharmaceuticals' Accumulated Expenses history runs 8 years deep, the most recent figure standing at $110.8 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 45.14% year-over-year to $110.8 million in Q1 2026; TTM through Mar 2026 was $110.8 million, a 45.14% increase from a year earlier, with the FY2025 full-year figure at $101.5 million, up 541.65% from the prior year.
• Accumulated Expenses advanced to $110.8 million in Q1 2026 per TARS's latest filing, from $101.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $110.8 million in Q1 2026 and bottomed at $2.8 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $10.8 million (2022), against an average of $29.2 million.
• Across the five-year window, Accumulated Expenses soared 1477.37% in 2022 and plunged 61.07% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $9.9 million in 2022, then soared by 139.06% to $23.7 million in 2023, then plunged by 33.21% to $15.8 million in 2024, then jumped by 541.65% to $101.5 million in 2025, then advanced by 9.18% to $110.8 million in 2026.
• Per Business Quant, the three latest TARS Accumulated Expenses figures stand at $110.8 million (Q1 2026), $101.5 million (Q4 2025), and $13.6 million (Q3 2025).